Background:
Influenza is regarded as an over-serious evoke infection present. Infection is typically constricted to the mucosal cells of the respiratory tract. Immunity is abbreviated and reinfection falls out due to the high mutation rate of the influenza virus. The aim of the study: Development of RNA vaccine against Influenza virus by bioinformatics and genetic engineering.
Type of Study: Screening experimental study.
Methodology:
In our study, we designed an RNA vaccine of haemagglutinin (HA) and neuraminidase (NA) of the Influenza virus by bioinformatics and genetic engineering. The particle size of the lipid nanoparticles vaccine delivery system was approximately 100 nm.
Results:
The vaccine showed 86% efficacy during preclinical trials while 78% during human clinical trials phases 1/2. It showed superior biological activity and fewer side effects than other vaccines such as the Influvac vaccine. The efficacy lasted for 12-14 months. The molecular mass of Haemagglutonin was approximately 66 KDa as determined by a mass spectrometer. As well the molecular mass of neuraminidase was found to be about 70 KDa. The protective neutralizing antibodies were produced against haemagglutinin.
Conclusion:

The vaccine, in our study, was effective as prophylaxis against viral infection with Influenza and mutant forms of this virus. It needs to be updated periodically to overcome the problem of the high mutation rate of the influenza virus.